

# Robert S Mckelvie

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1705286/robert-s-mckelvie-publications-by-citations.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40 papers	4,143 citations	23 h-index	43 g-index
43 ext. papers	4,997 ext. citations	10.7 avg, IF	4.37 L-index

#	Paper	IF	Citations
40	Irbesartan in patients with heart failure and preserved ejection fraction. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 2456-67	59.2	1307
39	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2021-31	59.2	440
38	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2009-20	59.2	382
37	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 1342-1433	3.8	330
36	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2032-43	59.2	199
35	Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 27-35	7.6	184
34	The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 168-81	3.8	157
33	The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 319-38	3.8	123
32	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. <i>Canadian Journal of Cardiology</i> , <b>2007</b> , 23, 21-45	3.8	110
31	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. <i>Canadian Journal of Cardiology</i> , <b>2010</b> , 26, 185-202	3.8	105
30	Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 561-8	7.6	80
29	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 3-16	3.8	77
28	Sprint training enhances ionic regulation during intense exercise in men. <i>Journal of Physiology</i> , <b>1997</b> , 501 ( Pt 3), 687-702	3.9	73
27	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 296-310	3.8	65
26	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , <b>2015</b> , 131, 43-53	16.7	58
25	Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1106-13	15.1	48
24	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 809-17	12.3	45

23	Effects of resistance training combined with moderate-intensity endurance or low-volume high-intensity interval exercise on cardiovascular risk factors in patients with coronary artery disease. <i>Journal of Science and Medicine in Sport</i> , <b>2015</b> , 18, 637-42	4.4	43
22	Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. <i>European Heart Journal</i> , <b>2003</b> , 24, 1727-34	9.5	42
21	Enhanced pulmonary and active skeletal muscle gas exchange during intense exercise after sprint training in men. <i>Journal of Physiology</i> , <b>1997</b> , 501 ( Pt 3), 703-16	3.9	37
20	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 249-63	3.8	36
19	Evidence based application of BNP/NT-proBNP testing in heart failure. <i>Clinical Biochemistry</i> , <b>2015</b> , 48, 236-46	3.5	30
18	Circulatory responses to weight lifting, walking, and stair climbing in older males. <i>Journal of the American Geriatrics Society</i> , <b>1996</b> , 44, 121-5	5.6	30
17	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 20-28	3.3	20
16	Brachial artery endothelial responses during early recovery from an exercise bout in patients with coronary artery disease. <i>BioMed Research International</i> , <b>2014</b> , 2014, 591918	3	18
15	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 478-486	7.9	17
14	Technology-Enabled Remote Monitoring and Self-Management - Vision for Patient Empowerment Following Cardiac and Vascular Surgery: User Testing and Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , <b>2016</b> , 5, e149	2	14
13	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1021-31	12.3	13
12	The journey of the frail older adult with heart failure: implications for management and health care systems. <i>Reviews in Clinical Gerontology</i> , <b>2014</b> , 24, 269-289		11
11	The effect of beta-blockade on plasma potassium concentrations and muscle excitability following static exercise. <i>Pflugers Archiv European Journal of Physiology</i> , <b>1998</b> , 436, 449-56	4.6	10
10	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1038.e5-9	3.8	8
9	The role of unregulated care providers in managing heart failure patients in long-term care facilities. <i>Journal of Clinical Nursing</i> , <b>2017</b> , 26, 849-861	3.2	7
8	The Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1566-1569	3.8	7
7	Development of a patient decision aid for people with refractory angina: protocol for a three-phase pilot study. <i>Health and Quality of Life Outcomes</i> , <b>2014</b> , 12, 93	3	6
6	An Update on the Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter. <i>CJC Open</i> , <b>2019</b> , 1, 198-205	2	4

5	Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. <i>CJC Open</i> , <b>2020</b> , 2, 321-327	2	3
4	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.. <i>Lancet, The</i> , <b>2022</b> , 399, 1391-1400	4 <sup>0</sup>	2
3	Origins of arterial and femoral venous acidBase responses during moderate-intensity bicycling exercise after glycogen depletion in men. <i>Equine and Comparative Exercise Physiology</i> , <b>2007</b> , 4, 123-133		1
2	The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , <b>2004</b> , 13, 245-53	5.9	1
1	The CREATE Method for Expressing Continuous Outcome Data in Absolute Terms for Use in Patient Treatment Decision Aids: A Validation Study. <i>Medical Decision Making</i> , <b>2015</b> , 35, 959-66	2.5	